You might also like
Alterity Therapeutics Limited (ATHE) is a biotechnology company specializing in the development of therapeutic drugs for neurodegenerative diseases, with a primary focus on Parkinsonian disorders and related movement disorders. The company is a development-stage enterprise, advancing its pharmaceutical products through early to mid-stage clinical trials. Alterity does not sell commercial products but generates revenue through government grants, licensing, research collaborations, and interest income.
- Research and Development in Neurodegenerative Diseases - Focuses on discovering and developing therapeutic drugs targeting Parkinsonian disorders, including Multiple System Atrophy (MSA), a rare and debilitating condition with no approved treatments.
- ATH434 - Lead drug candidate in Phase 2 clinical trials for MSA, designed to address the underlying pathology of the disease.
- PBT2 - Previously developed for Alzheimer’s and Huntington diseases, with completed Phase 1 and Phase 2 trials.
- Discovery Platform - Maintains a chemical library of over 1,000 validated compounds designed for oral bioavailability and blood-brain barrier penetration, targeting the interrelationship of metals and proteins in neurodegenerative diseases.
- Collaborative Research - Partners with leading scientists and institutions, conducting research at The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Dr. David Stamler Executive | Chief Executive Officer | None | Dr. Stamler has extensive experience in drug development, previously serving as CMO at Alterity and leading the development of ATH434 for neurodegenerative diseases. | View Report → |
Mr. Phillip Hains Executive | Chief Financial Officer and Company Secretary | Operates within Acclime Australia (formerly The CFO Solution) | Mr. Hains has over 30 years of experience in financial reporting and compliance, specializing in supporting public companies. | |
Mr. Brian Meltzer Board | Director | Director of Australia-Israel Chamber of Commerce; Chairman of Independence Australia | Mr. Meltzer has a background in investment banking and corporate advisory, with expertise in property transactions, venture capital, and syndications. | |
Mr. Geoffrey Kempler Board | Chairman of the Board | Chair of Hexima Ltd; Member of Turner Institute Advisory Board at Monash University | Founder of Alterity, Mr. Kempler has a background in psychology and investment, with significant contributions to the company's strategic direction. | |
Mr. Lawrence Gozlan Board | Director | Chief Investment Officer at Scientia Capital; Director of Opthea Limited | Mr. Gozlan is a life sciences investment specialist, leading Scientia Capital and holding directorships in several biotech companies. | |
Mr. Peter Marks Board | Director | Chairman of Newburyport Partners; Director of Noxopharm Limited, Iris Metals Limited, and Evergreen Lithium Limited | Mr. Marks has over 35 years of experience in corporate advisory and investment banking, focusing on life sciences and high-tech sectors. |
Recent press releases and 8-K filings for ATHE.
- Form 6-K for May 2025 filed by Alterity Therapeutics Limited under the Corporations Act 2001, reporting regulatory disclosures and significant events (document ).
- Substantial holding change details provided by The Bank of New York Mellon Corporation and its group, including adjustments in voting power of ordinary shares (document ).
- Annexures included that list share deposit, transfer details, and precise dates of changes, outlining the shifts in voting rights and interests (documents ).
- Alterity Therapeutics Ltd has received U.S. FDA Fast Track Designation for its lead candidate ATH434 aimed at treating Multiple System Atrophy, highlighting its potential to meet a high unmet medical need.
- This designation will allow for more frequent interactions with the FDA to facilitate an accelerated development and review process.
- ATH434-201 Phase 2 trial in MSA reported positive topline data with robust clinical efficacy, supporting continued advancement in disease modifying treatment.
- The ATH434-202 open-label trial in advanced MSA was completed in March 2025, with topline results expected mid-year.
- The company maintained a strong cash position with A$17.96M on March 31, 2025, and raised an additional A$27.1M post–quarter end to further support its activities.
- Multiple directors – The filing details changes to the securities interests of directors Peter Marks, Lawrence Gozlan, and Brian Meltzer, with updated holdings and options positions as of 07 April 2025 and changes effective on 24 April 2025.
- Securities and options adjustments – The document discloses adjustments in both direct and indirect holdings, including instruments such as fully paid ordinary shares and listed/unlisted options, with one director’s change involving an options issue.
- Compliance and transparency – The changes were reported under ASX listing rules and the Corporations Act, with confirmation that no trades occurred during a closed period requiring prior written clearance.
- Presentation Date: The company presented the ATH434-201 Phase 2 clinical trial results at the European MSA Symposium on 28 April 2025.
- Efficacy Findings: The trial demonstrated a 48% relative treatment effect at the 50 mg dose (p=0.02) and a 30% effect at the 75 mg dose (p=0.16) on the primary modified UMSARS Part I endpoint.
- Additional Outcomes: Secondary endpoints, including global clinical impression and orthostatic hypotension assessments, along with imaging data showing reduced brain iron accumulation, supported the potential of ATH434 in modifying disease progression.
- Corporate Update: CEO David Stamler, MD leads an updated corporate presentation emphasizing clinical stage biopharmaceutical development for neurodegenerative diseases, with a focus on the ATH434 program targeting Multiple System Atrophy .
- New ASX Quotation Application: Filed on April 22, 2025 for a new class of options with an exercise price of AUD 0.028, expiring on 26 February 2027, covering 1,222,300,911 options .
- Capital Raise Initiative: The new securities are issued to raise additional working capital at nil consideration per option .
- Forward-Looking Statements: The update includes statements outlining clinical progress and associated risks .
- Alterity Therapeutics Ltd filed an April 2025 Form 6-K report combining a top holders overview with an updated corporate presentation .
- The filing details the top 20 holders of its listed option security ATHOPTWC25 (expiring on February 26, 2027 at $0.028), including significant positions from UBS NOMINEES PTY LTD and CITICORP NOMINEES PTY LIMITED .
- CEO David Stamler, MD spearheads the update, highlighting the company’s focus on clinical stage biopharmaceutical development, particularly for neurodegenerative diseases .
- The update emphasizes the ATH434 program targeting Multiple System Atrophy and includes forward-looking statements outlining clinical progress and associated risks .
- The document also provides key corporate details, including the address at Level 5, 126 Phillip Street, Sydney NSW .
- Alterity Therapeutics announced encouraging new Phase 2 ATH434 trial data in patients with MSA, showing clinically significant improvement on the UMSARS Part I scale and a notable 48% reduction in clinical progression at the 50 mg dose, with target engagement evidenced by biomarker analyses and increased physical activity trends .
- Completed its second placement tranche, raising A$38.79M with key participation from the CEO, CFO, and majority of the Board to accelerate development and regulatory activities for ATH434 and neurodegenerative disease research .
- Filed a Form 6-K for April 2025 including Exhibit 99.1 titled "Becoming a substantial holder," officially signed by Chairman Geoffrey P. Kempler on April 9, 2025 .
- Issued 2,470,521,806 fully paid ordinary shares on 07 April 2025 in compliance with the Corporations Act .
- Disclosed changes to director interests affecting Peter Marks, Lawrence Gozlan, and Brian Meltzer, including placements at $0.011 per share and adjustments in fully paid shares and option positions .
- BNYMC Group holds 2,277,309,274 securities while BNYM acts as the depositary for the ADR program, holding 2,277,308,548 securities under the Deposit Agreement .
- The company filed a 6-K report on April 7, 2025, to apply for the quotation of its securities on the ASX.
- The application includes quoting 2,470,521,806 ordinary fully paid securities, along with additional planned issues such as 1,212,121,212 options.
- The filing also provides updated issued capital details showing 9,127,370,686 ordinary fully paid securities post-quotation.
- Alterity Therapeutics announced it will deliver an oral presentation on positive ATH434 Phase 2 trial results in Multiple System Atrophy at the AAN 2025 Annual Meeting.
- The filing also notes a poster presentation covering wearable sensor data and additional analyses, underscoring the robust clinical findings from the trial.